Dry Eye Syndrome Clinical Trials

Find Dry Eye Syndrome Clinical Trials Near You

Evaluation of a Novel Ocular Lubricating Eye Drop

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The objective of this 2-part study is to assess the safety and tolerability of the new ocular lubricating drop ABR2 during short-term use in subjects for the temporary relief of ocular discomfort due to dryness of the eye. In Part 1, participant will receive 1 drop of ABR2 in one eye and through assessments over a 1-hour period. In Part 2, participant will use 1 drop of ABR2 at least two times a day for 28-day period (may use up to 4 times a day as needed) This is a single arm, open label study with no placebo or comparative arm.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Are at least 18 years of age and have capacity to volunteer

• Are able to read (Part 2 only);

• Have signed an information and consent letter;

• Are willing to follow instructions and maintain the appointment schedule;

• Are willing to refrain from contact lens wear throughout the study period;

• Have a best corrected visual acuity of +0.20 LogMAR or better in each eye;

• Have an OSDI score ≥13 AND at least one of the following signs in at least one eye: Non-invasive tear film break-up time (NITBUT) \< 10 sec, AND/OR ocular surface staining (\> 5 corneal spots, and/ or \> 9 conjunctival spots)

Locations
Other Locations
Canada
Centre for Ocular Research & Education, School of Optometry & Vision Science, University of Waterloo
RECRUITING
Waterloo
Contact Information
Primary
CORE Studies
corestudies@uwaterloo.ca
519-888-4742
Backup
Ulli Stahl, PhD
ustahl@uwaterloo.ca
519-888-4742
Time Frame
Start Date: 2026-05
Estimated Completion Date: 2027-05
Participants
Target number of participants: 40
Treatments
Experimental: Part 1
Part 1 Participants
Experimental: Part 2
Part 2 Participants
Related Therapeutic Areas
Sponsors
Collaborators: University of Waterloo School of Optometry and Vision Science
Leads: Pleryon Therapeutics (Hangzhou) Limited

This content was sourced from clinicaltrials.gov